Threshold gets hypoxia PET imaging agent from Siemens Healthcare
Threshold Pharmaceuticals Inc. (developing drugs that target tumor hypoxia) has acquired Siemens Healthcare’s radiolabeled hypoxia positron emission tomography (PET) tracer (18F)HF4 (flortanidazole (18F)), which it will use as a companion diagnostic for its cancer therapeutics in development.
- Radiopharmaceuticals, Contrast Agents
- Diagnostic Imaging Equipment & Supplies
- Product Purchase
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.